The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.
Looking to invest their extensive cash reserves into financing their future growth, deep-pocketed corporate acquirers have traditionally been the biggest buyers of PE assets.